Metoject (Methotrexate)
Pre-filled injection pen for rheumatoid arthritis, psoriasis, and Crohn's disease
Metoject is a brand-name pre-filled injection pen containing methotrexate, one of the most widely prescribed disease-modifying anti-rheumatic drugs (DMARDs) in the world. Administered once weekly by subcutaneous injection, Metoject is primarily used to treat active rheumatoid arthritis, severe plaque psoriasis, psoriatic arthritis, and Crohn's disease. Methotrexate is included on the WHO Model List of Essential Medicines and is recommended as the first-line DMARD by both EULAR and ACR guidelines for rheumatoid arthritis.
Quick Facts: Metoject
Key Takeaways
- Metoject delivers methotrexate via a convenient pre-filled pen for once-weekly subcutaneous injection, improving bioavailability compared to oral methotrexate
- It is the first-line DMARD recommended by EULAR and ACR guidelines for rheumatoid arthritis, and is also effective for severe psoriasis and Crohn's disease
- Methotrexate must only be taken once per week — daily dosing can cause fatal toxicity; folic acid supplementation reduces side effects
- Regular blood monitoring (complete blood count, liver function, renal function) is mandatory throughout treatment
- Strictly contraindicated in pregnancy and breastfeeding due to teratogenic effects; effective contraception is required for both men and women
What Is Metoject and What Is It Used For?
Metoject contains the active substance methotrexate, which belongs to the group of medicines known as disease-modifying anti-rheumatic drugs (DMARDs) and antimetabolites. Methotrexate was originally developed as a chemotherapy agent in the 1940s, but at the much lower doses used in autoimmune disease, it acts primarily as an anti-inflammatory and immunomodulatory agent. Metoject is manufactured by medac GmbH and is available as a pre-filled pen for self-administration by subcutaneous injection.
At the molecular level, methotrexate inhibits the enzyme dihydrofolate reductase (DHFR), which is essential for the synthesis of DNA building blocks (purines and pyrimidines). At the low doses used in rheumatology and dermatology (typically 7.5–25 mg weekly), methotrexate exerts its therapeutic effect primarily by increasing extracellular adenosine concentrations. This adenosine release suppresses pro-inflammatory cytokines, including tumor necrosis factor alpha (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6), thereby reducing inflammation and joint damage.
The subcutaneous route of administration offered by the Metoject pen provides several advantages over oral methotrexate tablets. Studies published in Arthritis & Rheumatism have demonstrated that subcutaneous methotrexate achieves significantly higher bioavailability (approximately 85–95%) compared to oral administration (approximately 60–70%), particularly at doses above 15 mg per week. This improved absorption can translate into better clinical efficacy and may reduce gastrointestinal side effects such as nausea, which are common with oral methotrexate.
Approved Indications
Metoject is approved for the following conditions in adults:
- Active rheumatoid arthritis (RA): As a first-line DMARD to reduce inflammation, slow joint destruction, and improve physical function. Recommended by both EULAR 2022 and ACR 2021 guidelines as the anchor drug in RA treatment.
- Severe plaque psoriasis: For adults with moderate-to-severe psoriasis that has not responded adequately to conventional therapies including phototherapy, psoralen plus ultraviolet A (PUVA), and topical treatments.
- Psoriatic arthritis: To control joint inflammation and skin manifestations in patients with active psoriatic arthritis.
- Crohn's disease: For induction and maintenance of remission in moderate-to-severe Crohn's disease, particularly in steroid-dependent patients.
Additionally, methotrexate is frequently used off-label for conditions including lupus, vasculitis, sarcoidosis, ectopic pregnancy, and various other autoimmune and inflammatory disorders. However, Metoject is specifically indicated for the conditions listed above.
What Should You Know Before Taking Metoject?
Before starting treatment with Metoject, your prescribing physician will conduct a thorough assessment including blood tests (complete blood count, liver function tests, renal function, hepatitis B and C serology), chest radiography, and a review of your medical history. This pre-treatment evaluation is essential because methotrexate can affect the bone marrow, liver, lungs, and immune system. Understanding the contraindications, warnings, and precautions is critical for safe use.
Contraindications
- Known hypersensitivity to methotrexate or any of the excipients
- Pregnancy or are planning to become pregnant (methotrexate is a known teratogen)
- Breastfeeding (methotrexate is excreted in breast milk)
- Severe hepatic impairment (bilirubin >5 mg/dL or significant liver disease)
- Severe renal impairment (creatinine clearance <20 mL/min)
- Pre-existing severe bone marrow suppression (leukopenia, thrombocytopenia, significant anemia)
- Active serious infections including tuberculosis or HIV
- Severe immunodeficiency syndromes
- Active peptic ulcer disease or ulcerative stomatitis
- Alcohol abuse or alcoholic liver disease
- Concurrent use of live vaccines
Warnings and Precautions
Methotrexate must be administered once weekly only. Accidental daily dosing of methotrexate intended for weekly use has resulted in fatal toxicity. Patients and caregivers must clearly understand that Metoject is a once-per-week injection. Choose a specific day of the week and always inject on the same day.
Your doctor should discuss the following important precautions with you before and during treatment:
- Blood monitoring: Regular blood tests are essential. During the first 6 months, tests should be performed every 2–4 weeks; thereafter at least every 2–3 months. These include full blood count (FBC), liver function tests (ALT, AST, albumin), and renal function (creatinine, eGFR).
- Liver toxicity: Methotrexate can cause liver damage including fibrosis and cirrhosis. Alcohol must be avoided or strictly limited. Persistent elevation of liver enzymes may require dose reduction or discontinuation.
- Pulmonary toxicity: Methotrexate pneumonitis is a rare but potentially life-threatening complication. Seek immediate medical attention if you develop a dry cough, shortness of breath, or fever during treatment.
- Infection risk: Methotrexate suppresses the immune system, increasing susceptibility to infections including opportunistic infections. Report any signs of infection (fever, sore throat, persistent cough) to your doctor promptly.
- Vaccination: Live vaccines (e.g. MMR, varicella, yellow fever, live influenza) must be avoided during treatment. Inactivated vaccines may have reduced effectiveness.
- Skin cancer: An increased risk of lymphoma and skin cancers has been reported. Minimize sun exposure and use sun protection.
- Folic acid: Taking folic acid 5 mg once weekly (on a different day than methotrexate) significantly reduces side effects including mouth ulcers, nausea, and liver enzyme elevations, as supported by Cochrane systematic review evidence.
Pregnancy and Breastfeeding
Metoject is strictly contraindicated during pregnancy. Methotrexate is classified as a known human teratogen (FDA Pregnancy Category X). Exposure during pregnancy can cause:
- Spontaneous abortion (miscarriage) in up to 40–50% of exposures
- Severe birth defects including craniofacial abnormalities, limb defects, and central nervous system malformations (methotrexate embryopathy)
- Intrauterine growth restriction
- Fetal death
Women of childbearing potential: Effective contraception must be used during treatment and for at least 6 months after the last dose. A pregnancy test must be performed before starting treatment. If pregnancy occurs during treatment, immediate discontinuation and specialist counseling regarding the risk of adverse effects on the fetus are required.
Men: Methotrexate may affect sperm quality. Male patients should use effective contraception during treatment and for at least 3 months after the last dose. Men should not donate sperm during this period.
Breastfeeding: Metoject is contraindicated during breastfeeding because methotrexate is excreted in breast milk and may cause toxicity in the nursing infant.
Fertility: Methotrexate may impair fertility in both sexes. In women, it can cause menstrual irregularities and oligospermia in men. These effects are generally reversible upon discontinuation, though full recovery may take several months.
How Does Metoject Interact with Other Drugs?
Drug interactions with methotrexate can be clinically significant and potentially dangerous. Methotrexate is primarily eliminated by the kidneys through both glomerular filtration and active tubular secretion. Drugs that impair renal function or compete for tubular secretion can increase methotrexate levels, leading to enhanced toxicity. Additionally, drugs that also affect the bone marrow or liver can have additive toxic effects.
Major Interactions
| Drug / Drug Class | Interaction Mechanism | Clinical Effect | Recommendation |
|---|---|---|---|
| Trimethoprim/Sulfamethoxazole | Additive antifolate effect | Severe, potentially fatal pancytopenia | Combination is contraindicated |
| NSAIDs (ibuprofen, naproxen, diclofenac) | Reduced renal clearance of methotrexate | Increased methotrexate toxicity (bone marrow, GI, hepatic) | Use with caution; close monitoring required. Avoid high-dose NSAIDs |
| Probenecid | Inhibits tubular secretion of methotrexate | Markedly increased methotrexate levels | Combination should be avoided |
| Leflunomide | Additive hepatotoxicity and immunosuppression | Increased risk of liver damage and pancytopenia | Combination requires close monitoring of liver function and blood counts |
| Live vaccines | Immunosuppression by methotrexate | Risk of disseminated infection from live vaccine | Live vaccines are contraindicated |
| Penicillins (amoxicillin, piperacillin) | Reduced renal clearance of methotrexate | Increased methotrexate toxicity | Monitor blood counts closely if co-administered |
Minor Interactions
The following interactions are generally less severe but should still be communicated to your healthcare provider:
- Proton pump inhibitors (omeprazole, pantoprazole): May reduce renal clearance of methotrexate. Usually clinically insignificant at low doses but should be noted.
- Theophylline: Methotrexate may increase theophylline levels. Monitor theophylline levels if used concomitantly.
- Ciclosporin: Both drugs are immunosuppressants; increased risk of infection and toxicity. Can be used together under specialist supervision with enhanced monitoring.
- Folic acid (high doses): Very high doses of folic acid may reduce the efficacy of methotrexate. Standard supplementation of 5 mg weekly does not impair efficacy.
- Alcohol: Strongly increases the risk of hepatotoxicity. Patients should avoid or strictly limit alcohol consumption.
- Hepatotoxic drugs: Concurrent use of other hepatotoxic medications (e.g. azathioprine, retinoids, sulfasalazine) increases the risk of liver damage.
Always tell your doctor, pharmacist, or rheumatology nurse about all medications you are taking, including over-the-counter drugs (especially NSAIDs like ibuprofen), herbal supplements (especially St John's Wort), and vitamins. Keep an up-to-date medication list and bring it to every appointment.
What Is the Correct Dosage of Metoject?
Metoject should only be prescribed by physicians experienced in the use of methotrexate and who are fully aware of the risks of methotrexate therapy. The dose is individualized based on the indication, disease severity, patient weight, renal function, and response to treatment. It is critical that methotrexate is administered once per week only — never daily.
Adults
| Indication | Starting Dose | Usual Maintenance | Maximum Dose |
|---|---|---|---|
| Rheumatoid Arthritis | 7.5–15 mg once weekly | 15–20 mg once weekly | 25–30 mg/week |
| Psoriasis | 7.5 mg once weekly (test dose recommended) | 10–22.5 mg once weekly | 25 mg/week |
| Psoriatic Arthritis | 7.5–15 mg once weekly | 15–22.5 mg once weekly | 25 mg/week |
| Crohn's Disease | 15–25 mg once weekly | 15–25 mg once weekly | 25 mg/week |
For rheumatoid arthritis, EULAR 2022 guidelines recommend starting methotrexate at 10–15 mg per week with escalation by 5 mg every 2–4 weeks to a target of 20–25 mg per week, provided the drug is tolerated. Switching from oral to subcutaneous methotrexate (such as Metoject) is recommended when oral methotrexate shows insufficient response, as the improved bioavailability of the subcutaneous route may provide additional clinical benefit.
Children
Metoject may be used in children and adolescents (aged 3 years and older) for polyarticular forms of juvenile idiopathic arthritis (JIA) when the response to NSAIDs has been inadequate. The recommended dose is 10–15 mg/m2 body surface area per week. In cases of inadequate response, the dose may be increased to 20 mg/m2/week. Enhanced monitoring is required in pediatric patients, and treatment should be supervised by a pediatric rheumatologist.
Elderly
Dose reduction may be considered in elderly patients due to the age-related decline in liver and kidney function. Renal function should be carefully assessed before and during treatment. Monitoring intervals should be shorter in elderly patients. A lower starting dose of 7.5 mg per week is generally recommended, with cautious dose escalation based on tolerance and response.
Renal and Hepatic Impairment
In patients with mild renal impairment (creatinine clearance 20–50 mL/min), methotrexate dose should be reduced by 50% and renal function monitored closely. Metoject is contraindicated in severe renal impairment (creatinine clearance <20 mL/min). Patients with hepatic impairment require careful assessment; Metoject is contraindicated in severe liver disease.
How to Inject Metoject
Metoject is designed for self-administration after appropriate training from a healthcare professional. The injection is given subcutaneously (under the skin) in the abdomen or thigh. The pre-filled pen makes self-injection straightforward:
- Remove the pen from the refrigerator 15–30 minutes before injection to allow it to reach room temperature.
- Wash your hands thoroughly and choose an injection site on the abdomen (at least 5 cm from the navel) or the front of the thigh.
- Clean the injection site with an alcohol swab and allow it to air dry.
- Remove the pen cap and place the pen firmly against the skin at a 90-degree angle.
- Press the activation button and hold the pen in place for approximately 5–10 seconds until the injection is complete (you will hear or feel a click).
- Remove the pen and apply gentle pressure to the injection site with a cotton ball if needed.
- Dispose of the used pen in a sharps container. Never reuse or recap the pen.
Missed Dose
If you forget to take your weekly dose of Metoject, take it as soon as you remember, provided it is within 2 days of the scheduled dose. If more than 2 days have passed, skip the missed dose and take the next dose on your regular day. Do not take a double dose to make up for a missed one. Contact your doctor or rheumatology nurse if you are unsure what to do.
Overdose
Methotrexate overdose can be life-threatening. Symptoms of overdose include severe mucositis, bone marrow suppression (which may take 1–2 weeks to manifest), hepatotoxicity, and renal failure. The specific antidote is calcium folinate (leucovorin), which should be administered as soon as possible. If you suspect an overdose or have accidentally taken methotrexate more than once in a week, contact your local poison center or emergency services immediately.
What Are the Side Effects of Metoject?
Like all medicines, Metoject can cause side effects, although not everybody gets them. The frequency and severity of side effects depend on the dose used and the individual patient. Most side effects are dose-dependent and can be managed with dose adjustment, folic acid supplementation, or symptomatic treatment. However, some adverse effects are serious and require immediate medical attention.
Folic acid supplementation (typically 5 mg once weekly, taken on a different day than the methotrexate injection) is recommended by international guidelines and has been shown in a Cochrane systematic review to reduce gastrointestinal side effects, mouth ulcers, and liver enzyme elevations by approximately 40–60%.
Very Common
- Nausea and loss of appetite
- Elevated liver enzymes (transaminases AST/ALT)
- Stomatitis (mouth ulcers, inflammation of the oral mucosa)
- Abdominal pain
Common
- Headache, fatigue, and drowsiness
- Diarrhea
- Leukopenia (low white blood cell count)
- Thrombocytopenia (low platelet count)
- Anemia
- Rash, itching, and dermatitis
- Dizziness and light-headedness
- Injection site reactions (redness, swelling, itching)
- Hair thinning (alopecia)
Uncommon
- Interstitial pneumonitis (lung inflammation) — potentially fatal
- Liver fibrosis and fatty changes
- Pancytopenia (reduction of all blood cell types)
- Pharyngitis and upper respiratory infections
- Photosensitivity (increased sensitivity to sunlight)
- Herpes zoster (shingles) reactivation
- Gastrointestinal ulceration and bleeding
- Increased risk of infections (opportunistic infections)
Rare
- Severe bone marrow failure (agranulocytosis, aplastic anemia)
- Liver cirrhosis
- Pulmonary fibrosis
- Lymphoproliferative disorders and lymphoma (usually reversible upon discontinuation)
- Severe cutaneous reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis)
- Renal failure
- Anaphylactic reactions
- Neurotoxicity (confusion, seizures, leukoencephalopathy)
- Sepsis and serious opportunistic infections (e.g., Pneumocystis jirovecii pneumonia)
Contact your doctor or go to the emergency department immediately if you experience any of the following while taking Metoject:
- Unexplained fever, sore throat, or signs of infection (may indicate bone marrow suppression)
- Persistent dry cough, shortness of breath, or chest pain (may indicate lung toxicity)
- Unusual bleeding or bruising (may indicate low platelet count)
- Severe mouth ulcers or painful swallowing
- Yellowing of the skin or eyes (jaundice — may indicate liver damage)
- Dark urine or significantly reduced urine output
- Severe skin reactions or widespread rash
How Should You Store Metoject?
Proper storage of Metoject is important to ensure the medication remains effective and safe to use. As a biologic-sensitive product, incorrect storage can degrade the active substance and potentially render the injection ineffective or harmful.
- Temperature: Store in a refrigerator at 2–8°C. Do not freeze. If the solution has been frozen, it must not be used.
- Light protection: Keep the pre-filled pens in the original carton to protect from light.
- Room temperature: Metoject may be stored at room temperature (up to 25°C) for a single period of up to 6 months. Once removed from the refrigerator for room temperature storage, note the new expiry date and do not return it to the refrigerator.
- Before use: Remove the pen from the refrigerator 15–30 minutes before injection to reach room temperature, as cold injections may be more uncomfortable.
- Visual inspection: Before use, check that the solution is clear and yellow in color. Do not use if the solution is cloudy, discolored, or contains visible particles.
- Disposal: Dispose of used pens in a sharps container. Do not dispose of in household waste. Follow local regulations for disposal of cytotoxic waste.
- Keep out of reach of children: Methotrexate is toxic and accidental exposure in children can cause serious harm.
Do not use Metoject after the expiry date printed on the pen label and outer carton. The expiry date refers to the last day of that month. If you notice any damage to the pen or packaging, do not use it and return it to your pharmacy.
What Does Metoject Contain?
Understanding what is in your medication is important, particularly if you have known allergies or sensitivities to certain substances. Metoject contains a minimal number of excipients, which is typical for parenteral (injectable) formulations.
Active Ingredient
The active substance is methotrexate. Each pre-filled pen contains methotrexate disodium dissolved in a ready-to-use solution. The pens are available in the following strengths:
- Metoject 7.5 mg: contains 7.5 mg methotrexate in 0.15 mL solution (50 mg/mL)
- Metoject 10 mg: contains 10 mg methotrexate in 0.20 mL solution
- Metoject 12.5 mg: contains 12.5 mg methotrexate in 0.25 mL solution
- Metoject 15 mg: contains 15 mg methotrexate in 0.30 mL solution
- Metoject 17.5 mg: contains 17.5 mg methotrexate in 0.35 mL solution
- Metoject 20 mg: contains 20 mg methotrexate in 0.40 mL solution
- Metoject 22.5 mg: contains 22.5 mg methotrexate in 0.45 mL solution
- Metoject 25 mg: contains 25 mg methotrexate in 0.50 mL solution
- Metoject 27.5 mg: contains 27.5 mg methotrexate in 0.55 mL solution
- Metoject 30 mg: contains 30 mg methotrexate in 0.60 mL solution
Excipients (Inactive Ingredients)
- Sodium chloride: Used to adjust the osmolality of the solution to make it compatible with body fluids.
- Sodium hydroxide: Used to adjust the pH of the solution to an appropriate level for injection.
- Water for injections: The solvent base of the formulation.
Metoject is preservative-free, which means each pen is for single use only. The solution is clear and yellow in color. The pen should not be used if the solution appears cloudy, discolored, or contains particulate matter.
Metoject contains less than 1 mmol sodium (23 mg) per dose, meaning it is essentially sodium-free. This is relevant for patients on a sodium-restricted diet.
Frequently Asked Questions About Metoject
Metoject is a pre-filled pen that delivers methotrexate by subcutaneous injection, while methotrexate tablets are taken orally. The key differences are: (1) Subcutaneous methotrexate has higher and more consistent bioavailability (85–95%) compared to oral tablets (60–70%), especially at doses above 15 mg/week; (2) Subcutaneous administration often causes fewer gastrointestinal side effects such as nausea and vomiting; (3) The pre-filled pen format makes self-injection convenient and allows accurate dosing. Your doctor may recommend switching from oral to subcutaneous methotrexate if you are not responding adequately to tablets or experiencing significant GI side effects.
Methotrexate is a slow-acting medication. It typically takes 4–8 weeks before you notice any improvement, and the full therapeutic benefit may not be apparent for 3–6 months. This is why it is classified as a disease-modifying agent rather than a symptomatic treatment. During the initial weeks, your doctor may prescribe additional medications such as corticosteroids or NSAIDs to control symptoms while waiting for methotrexate to take effect. It is important to continue taking Metoject as prescribed even if you do not feel an immediate benefit.
Yes, you can travel with Metoject, but some preparation is needed. Carry the pens in a cool bag with ice packs (2–8°C) during transit. Note that Metoject can be kept at room temperature (up to 25°C) for up to 6 months if refrigeration is unavailable. When flying, always carry Metoject in your hand luggage (not checked baggage, as cargo holds may freeze). Bring a letter from your doctor confirming you need to carry injectable medication and sharps. Check entry requirements for your destination country regarding prescription medications. Do not forget to carry enough sharps disposal containers for your trip.
Accidental double dosing of methotrexate in a single week is a medical event that requires immediate attention. Contact your doctor, pharmacist, or poison center right away. Depending on the dose taken and your individual risk factors, your doctor may recommend monitoring with blood tests, administration of folinic acid (leucovorin) as an antidote, or hospital observation. Even if you feel well immediately after a double dose, bone marrow effects may not appear for 7–14 days, so blood monitoring is essential. Never take an extra dose to "catch up" on a missed injection.
Alcohol should be avoided or very strictly limited during Metoject therapy. Both methotrexate and alcohol are metabolized by the liver, and their combined use significantly increases the risk of hepatotoxicity (liver damage), including fibrosis and cirrhosis. International guidelines from EULAR and ACR recommend either complete abstinence or very minimal alcohol intake. Your doctor will monitor your liver function with regular blood tests (ALT, AST, albumin), and elevated liver enzymes may require dose reduction or temporary interruption. If you have any history of liver disease or heavy alcohol use, this should be discussed with your doctor before starting treatment.
Folic acid supplementation is recommended because methotrexate works partly by blocking folate metabolism. This antifolate effect contributes to many of the common side effects including mouth ulcers, nausea, liver enzyme elevations, and bone marrow suppression. A Cochrane systematic review confirmed that folic acid supplementation reduces gastrointestinal side effects by 26% and liver enzyme abnormalities by up to 77%, without significantly reducing methotrexate's therapeutic efficacy. The standard recommendation is 5 mg folic acid once per week, taken on a different day than your Metoject injection. Some doctors prescribe folic acid on multiple days per week (excluding the methotrexate day) for patients with more pronounced side effects.
References
- Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Annals of the Rheumatic Diseases. 2023;82(1):3-18. doi:10.1136/ard-2022-223356
- Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care & Research. 2021;73(7):924-939. doi:10.1002/acr.24596
- European Medicines Agency. Metoject - Summary of Product Characteristics. EMA/H/C/000983. www.ema.europa.eu
- Shea B, Swinden MV, Tanjong Ghogomu E, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database of Systematic Reviews. 2013;(5):CD000951. doi:10.1002/14651858.CD000951.pub2
- Braun J, Kästner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis. Arthritis & Rheumatism. 2008;58(1):73-81. doi:10.1002/art.23144
- World Health Organization. WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023. www.who.int
- Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82(6):1445-1486. doi:10.1016/j.jaad.2020.02.044
- Visser K, Katchamart W, Loza E, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis. Annals of the Rheumatic Diseases. 2009;68(7):1086-1093. doi:10.1136/ard.2008.094474
Editorial Team
This article was written by the iMedic Medical Editorial Team, comprising licensed physicians specializing in rheumatology, dermatology, and clinical pharmacology. All content is based on international evidence-based guidelines (EULAR, ACR, EMA, WHO) and peer-reviewed research.
Independently reviewed by the iMedic Medical Review Board, an interdisciplinary panel of specialist physicians. Content follows the GRADE evidence framework and is updated when new guidelines or significant evidence emerges. Last review: January 2026.
iMedic is committed to providing accurate, evidence-based medical information with no commercial funding or pharmaceutical sponsorship. All content is peer-reviewed, fact-checked against primary sources, and regularly updated. For full details, see our Editorial Standards page. To report an error or suggest an update, please contact us.